Reduction of nitrogen oxides by injection of urea in the freeboard of a pilot scale fluidized bed combustor

The ‘thermal deNOx’ process using urea has been investigated in a 1 MW fluidized bed combustor. NOx reductions of up to 76% were obtainable by using this method. The experimental results show that urea is at least as active as NH3, which is commonly used in this application, but which is far more toxic and corrosive. Emission levels of 200 mg m−3 for NOx could be achieved by injecting the urea at a height of 2 m above the distribution plate in a molar ratio urea:NOx = 1.5. The SO2 emission value also appeared to be reduced when the urea was injected at a urea: NOx molar ratio > 4

Intercomparison of phenological transition dates derived from the PhenoCam Dataset V1.0 and MODIS satellite remote sensing

Phenology is a valuable diagnostic of ecosystem health, and has applications to environmental monitoring and management. Here, we conduct an intercomparison analysis using phenological transition dates derived from near-surface PhenoCam imagery and MODIS satellite remote sensing. We used approximately 600 site-years of data, from 128 camera sites covering a wide range of vegetation types and climate zones. During both “greenness rising” and “greenness falling” transition phases, we found generally good agreement between PhenoCam and MODIS transition dates for agricultural, deciduous forest, and grassland sites, provided that the vegetation in the camera field of view was representative of the broader landscape. The correlation between PhenoCam and MODIS transition dates was poor for evergreen forest sites. We discuss potential reasons (including sub-pixel spatial heterogeneity, flexibility of the transition date extraction method, vegetation index sensitivity in evergreen systems, and PhenoCam geolocation uncertainty) for varying agreement between time series of vegetation indices derived from PhenoCam and MODIS imagery. This analysis increases our confidence in the ability of satellite remote sensing to accurately characterize seasonal dynamics in a range of ecosystems, and provides a basis for interpreting those dynamics in the context of tangible phenological changes occurring on the ground

The star formation history of RCW 36

Recent studies of massive-star forming regions indicate that they can contain multiple generations of young stars. These observations suggest that star formation in these regions is sequential and/or triggered by a previous generation of (massive) stars. Here we present new observations of the star forming region RCW 36 in the Vela Molecular Ridge, hosting a young cluster of massive stars embedded in a molecular cloud complex. In the periphery of the cluster several young stellar objects (YSOs) are detected which produce bipolar jets (HH 1042 and HH 1043) demonstrating that these objects are still actively accreting. The VLT/X-shooter spectrum of the jet structure of HH 1042 provides detailed information on the physical conditions and kinematical properties of the jet plasma. From this information the YSO's accretion history can be derived. Combining the photometric and spectroscopic observations of RCW 36 gives insight into the formation process of individual stars and the star formation history of this young massive-star forming region.Comment: 10 pages, 5 figures, to appear in the proceedings of the ESO workshop "Circumstellar Dynamics at High Resolution", Foz do Iguacu (Br), Feb 2012, eds. A. Carciofi and T. Riviniu

Orbital Characteristics of the Subdwarf-B and F V Star Binary EC~20117-4014(=V4640 Sgr)

Among the competing evolution theories for subdwarf-B (sdB) stars is the binary evolution scenario. EC~20117-4014 (=V4640~Sgr) is a spectroscopic binary system consisting of a pulsating sdB star and a late F main-sequence companion (O'Donoghue et al. 1997), however the period and the orbit semi-major axes have not been precisely determined. This paper presents orbital characteristics of the EC 20117-4014 binary system using 20 years of photometric data. Periodic Observed minus Calculated (O-C) variations were detected in the two highest amplitude pulsations identified in the EC 20117-4014 power spectrum, indicating the binary system's precise orbital period (P = 792.3 days) and the light-travel time amplitude (A = 468.9 s). This binary shows no significant orbital eccentricity and the upper limit of the eccentricity is 0.025 (using 3 $\sigma$ as an upper limit). This upper limit of the eccentricity is the lowest among all wide sdB binaries with known orbital parameters. This analysis indicated that the sdB is likely to have lost its hydrogen envelope through stable Roche lobe overflow, thus supporting hypotheses for the origin of sdB stars. In addition to those results, the underlying pulsation period change obtained from the photometric data was $\dot{P}$ = 5.4 ($\pm$0.7) $\times$ $10^{-14}$ d d$^{-1}$, which shows that the sdB is just before the end of the core helium-burning phase

Events as spaces for upgrading

This study contributes to the literature dealing with upgrading of the Chinese automotive industry by analysing the role of events in the upgrading process. By combining literature on temporary clusters with that of knowledge sourcing and upgrading, we investigate how firms use events for upgrading. To do so, we systematically analyse a number of upgrading mechanisms. Moreover we analyse how event organisers can influence these mechanisms, and identify a number of barriers that may hinder the process of upgrading during events. Our empirical study of two automotive events in Shanghai reveals that firms use events particularly for monitoring, to access global buzz, and for the development of new global pipelines. Mobility turned to be less relevant. Event organisers act as ‘temporary cluster managers’, and influence upgrading via three types of policies: content policy, matchmaking policy and access policy. Identified barriers include defensive strategies of exhibitors, a focus on trade, and the large size of the show.. These barriers hinder monitoring and access to global buzz and pipelines in particular

Pharmaceutical compounding of orphan active ingredients in Belgium : how community and hospital pharmacists can address the needs of patients with rare diseases

Background: Pharmaceutical compounding of orphan active ingredients can offer cost-effective treatment to patients when no other drug product is available for a rare disease or during periods of drug product shortages. Additionally, it allows customized therapy for patients with rare diseases. However, standardized compounding formulas and procedures, and monographs are required to ensure the patients' safety. Results: Standardized formulas and compounding procedures were developed for seven orphan active ingredients (L-arginine, sodium benzoate, sodium phenylbutyrate, L-carnitine, chenodesoxycholic acid, primaquine phosphate, pyridoxal phosphate) and one non-orphan molecule (sodium perchlorate) regularly compounded by hospital pharmacists for extemporaneous use. The stability of these formulations was evaluated over 3months at refrigerated (5 degrees C) and standard storage conditions (25 degrees C/60%RH) using HPLC-based assays and a suitable shelf life was assigned to the formulations. Additionally, suitable analytical methods for quality control of formulations of pyridoxal phosphate and sodium perchlorate were developed as monographs for these components were not available in the European Pharmacopeia or United States Pharmacopeia. Conclusions: Availability of compounding formulas and protocols, as well as stability information, for orphan active ingredients can improve patients' access to treatment for rare diseases. Such data were collected for seven orphan active ingredients to treat patients with rare diseases when no other treatment is available. More efforts are needed to develop standardized formulas and compounding procedures for additional orphan active ingredients whose clinical efficacy is well-known but which are not available as products with a marketing authorization. Additionally, a legal framework at EU level is required to enable the full potential of pharmaceutical compounding for orphan active ingredients